Caspian: Os Results from a Randomised Phase 3 Study of First-Line Durvalumab +/- Tremelimumab plus Chemotherapy in ES-SCLC

ONCOLOGY RESEARCH AND TREATMENT(2020)

引用 0|浏览9
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要